VanEck Semiconductor ETF vs GeneDx Holdings Corp — how do they compare? VanEck Semiconductor ETF trades at $584.06, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SMH | WGS | |
|---|---|---|
52-Week High | $668.91 | $167.51 |
52-Week Low | $283.95 | $34.51 |
Market Cap | — | $1.80B |
Sector | — | Technology |
Enterprise Value | — | $1.80B |
Signals from Pluang's Aura AI — not financial advice
SMH trades at $584.08, up 5.08% in the last 24 hours, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The semiconductor ETF faces mixed sentiment as AI-driven chip stocks correct despite strong Q2 earnings. Recent institutional buying by firms like Empirical Wealth Management and Assetmark Inc. contrasts with broader market concerns about semiconductor sector rotation and China's potential export controls on AI technologies.
Near-term outlook remains cautious due to technical bearish signals and sector volatility, though oversold RSI levels suggest potential for a rebound. Key risks include geopolitical tensions, AI capex slowdown fears, and concentrated portfolio exposure. The ETF's performance hinges on semiconductor earnings momentum and hyperscaler spending trends through 2027.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →